Skip to main content
SpringerLink
Log in

Ten-Year Survivorship in Patients with Metastatic Gastrointestinal Stromal Tumors

Annals of Surgical Oncology volume 29, pages 7123–7132 (2022)Cite this article

Abstract

Introduction

Patients developing metastatic gastrointestinal stromal tumors (mGIST) have heterogenous disease biology and oncologic outcomes; prognostic factors are incompletely characterized. We sought to evaluate predictors of 10-year metastatic survivorship in the era of tyrosine kinase inhibitor (TKI) therapy.

Methods

We reviewed patients with mGIST treated at our Comprehensive Cancer Center from 2003 to 2019, including only patients with either mortality or 10 years of follow-up. Ten-year survivorship was evaluated with logistic regression.

Results

We identified 109 patients with a median age of 57 years at mGIST diagnosis. Synchronous disease was present in 57% (n = 62) of patients; liver (n = 48, 44%), peritoneum (n = 40, 37%), and liver + peritoneum (n = 18, 17%) were the most common sites. Forty-six (42%) patients were 10-year mGIST survivors. Following mGIST diagnosis, radiographic progression occurred within 2 years in 53% (n = 58) of patients, 2–5 years in 16% (n = 17), and 5–10 years in 16% (n = 17), with median survival of 32, 76, and 173 months, respectively. Seventeen (16%) patients had not progressed by 10 years.

Fifty-two (47%) patients underwent metastasectomy, which was associated with improved progression-free survival (hazard ratio 0.63, p = 0.04). In patients experiencing progression, factors independently associated with 10-year survivorship were age (odds ratio [OR] 0.96, p = 0.03) and time to progression (OR 1.71/year, p < 0.001).

Conclusions

Ten-year survivorship is achievable in mGIST in the era of TKIs and is associated with younger age and longer time to first progression, while metastasectomy is associated with longer time to first progression. The role of metastasectomy in the management of patients with disease progression receiving TKI therapy merits further study.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Human Pathol. 1999;30(10):1213–20.

    Article  CAS  Google Scholar 

  2. Corless CL, Heinrich MC. Molecular pathobiology of gastrointestinal stromal sarcomas. Ann Rev Pathol. 2008;3(1):557–86.

    Article  CAS  Google Scholar 

  3. Yang DY, Wang X, Yuan WJ, Chen ZH. Metastatic pattern and prognosis of gastrointestinal stromal tumor (GIST): a SEER-based analysis. Clin and Trans Oncol. 2019;21(12):1654–62.

    Article  CAS  Google Scholar 

  4. Patnaik S, Jyotsnarani Y, Rammurti S. Radiological features of metastatic gastrointestinal stromal tumors. J Clin Imag Sci. 2012;2:43.

    Article  Google Scholar 

  5. Joensuu H, Vehtari A, Riihimäki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012;13(3):265–74.

    Article  Google Scholar 

  6. Gold JS, van der Zwan SM, Gönen M, et al. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Ann Surg Oncol. 2007;14(1):134–42.

    Article  Google Scholar 

  7. van der Graaf WTA, Tielen R, Bonenkamp JJ, Lemmens V, Verhoeven RHA, de Wilt JHW. Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era. The British J Surg. 2018;105(8):1020–7.

    Article  Google Scholar 

  8. Demetri GD, Rankin CJ, Benjamin RS, et al. Long-term disease control of advanced gastrointestinal stromal tumors (GIST) with imatinib (IM): 10-year outcomes from SWOG phase III intergroup trial S0033. J Clin Oncol. 2014;32(15 Suppl):10508.

    Article  Google Scholar 

  9. Raut CP, Espat NJ, Maki RG, et al. Efficacy and tolerability of 5-year adjuvant imatinib treatment for patients with resected intermediate- or high-risk primary gastrointestinal stromal tumor: the PERSIST-5 clinical trial. JAMA Oncol. 2018;4(12):e184060.

    Article  Google Scholar 

  10. Hompland I, Bruland ØS, Hølmebakk T, et al. Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: analysis of a large, single-institution cohort. Acta oncologica. 2017;56(10):1317–23.

    Article  Google Scholar 

  11. Kim JH, Ryu MH, Yoo C, et al. Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience. Cancer Med. 2019;8(3):1034–43.

    Article  CAS  Google Scholar 

  12. Heinrich MC, Rankin C, Blanke CD, et al. Correlation of long-term results of imatinib in advanced gastrointestinal stromal tumors with next-generation sequencing results: analysis of phase 3 swog intergroup trial S0033. JAMA Oncol. 2017;3(7):944–52.

    Article  Google Scholar 

  13. Call JW, Wang Y, Montoya D, Scherzer NJ, Heinrich MC. Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from life raft group registry. Clin Sarcoma Res. 2019;9:4.

    Article  Google Scholar 

  14. Sutton TL, Walker BS, Billingsley KG, et al. Hepatic metastases in gastrointestinal stromal tumors: oncologic outcomes with curative-intent hepatectomy, resection of treatment-resistant disease, and tyrosine kinase inhibitor therapy alone. HPB (Oxford). 2022;24(6):986–93.

    Article  Google Scholar 

  15. Bamboat ZM, DeMatteo RP. Metastasectomy for gastrointestinal stromal tumors. J Surg Oncol. 2014;109(1):23–7.

    Article  Google Scholar 

  16. Sutton TL, Walker BS, Billingsley KG, et al. Disease-free interval is associated with oncologic outcomes in patients with recurrent gastrointestinal stromal tumor. Annals Surg Oncol. 2021;28(12):7912–20.

    Article  Google Scholar 

Download references

Funding

MCH received partial salary support from the following sources: a research grant from the Jonathan David Foundation, a VA Merit Review Grant (I01BX005358), and from NCI R21 Grant (R21CA263400).

Author information

Authors and Affiliations

  1. Department of Surgery, Division of General Surgery, Oregon Health & Science University, Portland, OR, USA

    Thomas L. Sutton MD, Brett S. Walker MD & Brett C. Sheppard MD

  2. Department of Surgery, Yale School of Medicine, New Haven, CT, USA

    Kevin G. Billingsley MD

  3. Department of Pathology, Oregon Health & Science University, Portland, OR, USA

    Christopher L. Corless MD PhD

  4. Department of Medicine, Division of Hematology/Oncology, Portland VA Health Care System and Oregon Health & Science University, Knight Cancer Institute, Portland, OR, USA

    Michael C. Heinrich MD FACP

  5. Department of Surgery, Division of Surgical Oncology, Oregon Health & Science University, Knight Cancer Institute, Portland, OR, USA

    Skye C. Mayo MD MPH

Authors
  1. Thomas L. Sutton MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brett S. Walker MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kevin G. Billingsley MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christopher L. Corless MD PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Brett C. Sheppard MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michael C. Heinrich MD FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Skye C. Mayo MD MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Skye C. Mayo MD MPH.

Ethics declarations

Disclosure

Michael Heinrich receives consulting fees from Novartis, Deciphera Pharmaceuticals, Blueprint Medicines, and Theseus Pharmaceuticals, and holds multiple patents on the diagnosis and/or treatment of GIST. One patent on the treatment of GIST has been licensed by OHSU to Novartis. Thomas L. Sutton, Brett S. Walker, Kevin G. Billingsley, Christopher L. Corless, Brett C. Sheppard, and Skye C. Mayo have no conflicts of interest to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sutton, T.L., Walker, B.S., Billingsley, K.G. et al. Ten-Year Survivorship in Patients with Metastatic Gastrointestinal Stromal Tumors. Ann Surg Oncol 29, 7123–7132 (2022). https://doi.org/10.1245/s10434-022-12063-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-022-12063-5

Keywords

search

Navigation